Trump Expected to Loosen Psychedelic Restrictions

The administration is set to pivot on drug policy by supporting clinical trials for compounds such as psilocybin and ibogaine.

This shift reflects a growing bipartisan interest in the therapeutic potential of psychedelics for mental health conditions that have proven resistant to traditional medicine.

The upcoming order will direct federal agencies to reduce regulatory hurdles and increase funding for research into these substances.

While the move is welcomed by advocates, it has also raised questions about the long-term safety and oversight of such treatments.